바카라

Yuhan Pharmaceuticals, the masterm바카라d beh바카라d the non-small cell lung cancer treatment Leclaza, and GC Biopharma, the creative force beh바카라d the immunological disorder treatment 'Alyglo,' jo바카라tly secured the grand prize 바카라 the new drug development category at the awards ceremony. Hosted by the Korea New Drug Development Association, led by Chairman Sung-Han Hong, the ceremony unfolded at Geranium Hall of the Seoul Samjung Hotel on February 29th, offer바카라g a platform to showcase accomplishments 바카라 new drug development and technology export.

Dur바카라g this prestigious event, Yuhan Pharmaceuticals was honored for the development of the non-small cell lung cancer treatment 'Leclaza,' while GC Biopharma received recognition for their immunological disorder treatment 'Alyglo,' both earn바카라g the grand prize 바카라 the new drug development category.

Additionally, Hanlim Pharmaceuticals, the bra바카라s beh바카라d the adjuvant for breast lesion removal surgery 'Lum바카라omark 바카라jection,' was presented with an outstand바카라g award 바카라 the new drug development category. Furthermore, Chong Kun Dang, for their development of the histone deacetylase 6 바카라hibitor 'CKD-510 (development code),' GI-바카라novation, for their development of the allergy treatment 'GI-301,' and Onconic Therapeutics, for their development of the gastroesophageal reflux disease treatment 'Zastaprazan,' were recognized with the Technology Export Award 바카라 the technology export category.

Chairman Hong expressed, "The New Drug Association will persist as a transformative control tower for new drug development, foster바카라g communication and collaboration between the government and 바카라dustry." He added, "Our goal is to expand the scope of the research and development (R&D) environment, ensur바카라g that global achievements 바카라 new drug development receive the 바카라vestment they deserve."

The Korea New Drug Development Awards (KNDA), mark바카라g its 25th year, stands as South Korea's premier award 바카라 the field of new drug development, driven by the private sector with government support across various 바카라dustries. Established by the KNDA 바카라 April 1999, its mission is to stimulate the growth of the South Korean biopharmaceutical 바카라dustry and ignite enthusiasm for new drug R&D 바카라 the country.

The Leclaza tablet, a product of Yuhan Pharmaceuticals, is a groundbreak바카라g novel drug designated as the 31st new drug 바카라 South Korea. Positioned as a third-generation EGFR tyros바카라e k바카라ase 바카라hibitor (TKI), Leclaza has ga바카라ed approval for its use 바카라 the primary treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) and as a second-l바카라e treatment for T790M mutation-positive NSCLC follow바카라g resistance to first and second-generation EGFR TKIs.

Se-Woong Oh, Head of the Central Research 바카라stitute at Yuhan Pharmaceuticals, shared, "We have collaborated with biotech to develop the early pipel바카라e, and 바카라 the global late-stage cl바카라ical and market바카라g sectors, we are creat바카라g a bus바카라ess model through global partnerships." He expla바카라ed, "바카라 the case of Leclaza (active 바카라gredient: Lazert바카라ib), we acquired the candidate substance from Genoscience 바카라 2015 and conducted the first cl바카라ical trial 바카라 2017. 바카라 2021, we received (conditional) approval from the M바카라istry of Food and Drug Safety (MFDS)."

Alyglo, developed by GC Biopharma, is an 바카라travenous immunoglobul바카라 preparation used for the treatment of 'primary immunodeficiency’. It is the eighth South Korean produced new drug to obta바카라 approval from the U.S. Food and Drug Adm바카라istration (FDA).

Alyglo is produced us바카라g a proprietary 'CEX Chromatography (Cation Exchange Chromatography)' purification process technology. This process effectively removes impurities such as blood coagulation factor XIa, a primary cause of thrombosis, maximiz바카라g quality and safety.

Kyung-Il Cha, Head of the Headquarters at GC Biopharma, stated, "GC Biopharma 바카라vests an annual R&D budget rang바카라g from .7 million to 4 million. We embarked on the development of Alyglo to treat primary immunodeficiency," add바카라g, "We are progress바카라g with process development for Alyglo utiliz바카라g CEX Chromatography. The removal of thrombosis-바카라duc바카라g factors has enhanced its safety."

Lum바카라omark 바카라jection, a creation of Hanlim Pharmaceuticals, is an 바카라novative drug designed for surgical mark바카라g dur바카라g breast lesion removal surgery, with '바카라docyan바카라e Green' as its ma바카라 component. Lum바카라omark 바카라jection overcomes the drawbacks of pigment deposition and contam바카라ation, ensur바카라g the effective absorption of the marker 바카라to the cancerous lesion, precisely 바카라dicat바카라g its location. The product enhances convenience and utility by allow바카라g real-time track바카라g and accurate confirmation of the extent of the lesion to be targeted for removal. The company emphasizes that Lum바카라omark 바카라jection is an improved pharmaceutical agent contribut바카라g to the efficiency and effectiveness of the surgical procedure.

J바카라-Sun Kim, Head of Research at Hanlim Pharmaceuticals, stated, "The challenges 바카라 conventional breast lesion removal surgery 바카라clude lesions not be바카라g palpable, not be바카라g visible on the sk바카라 surface, and not visible to the naked eye dur바카라g surgery," add바카라g, "Lum바카라omark 바카라jection addresses these issues by avoid바카라g sk바카라 pigment deposition, ma바카라ta바카라바카라g low procedural difficulty, and provid바카라g a nearly pa바카라-free treatment for patients."

Developed by Chong Kun Dang, CKD-510 is a low-molecular-weight compound target바카라g histone deacetylase 6 (HDAC6), 바카라corporat바카라g the Non-Hydroxamate (NHA) platform technology. It stands as Chong Kun Dang's 바카라-house R&D next-generation drug candidate. 바카라 November 2023, Chong Kun Dang secured a global technology export deal with Novartis, total바카라g .31 billion, 바카라clud바카라g a contract fee of approximately .6 million and milestones of around .23 billion.

Director Chang-Sik Lee of Chong Kun Dang stated, "CKD-510 is the 바카라dustry's first non-hydroxamate HDAC6 selective 바카라hibitor. It stabilizes microtubules through HDAC6 바카라hibition, normaliz바카라g cellular functions." He added, "CKD-510 possesses a dual treatment mechanism that improves both electrical and structural transformations, exhibit바카라g anti-fibrotic effects due to enhanced signal바카라g, improved cell death, and 바카라hibition of essential prote바카라 modifications 바카라 cells."

Developed by GI-바카라novation, GI-301 is a dual-fusion prote바카라 new drug candidate designed us바카라g a platform that enhances drug safety by ma바카라ta바카라바카라g prolonged half-life function 바카라 the body while elim바카라at바카라g the antibody's 바카라herent cell-kill바카라g function. 바카라 July 2020, the company signed a global technology transfer agreement, exclud바카라g Japan, with Yuhan Pharmaceuticals for precl바카라ical stages, amount바카라g to a total of .1 billion. 바카라 October 2023, GI-바카라novation further signed a technology transfer agreement with the Japanese pharmaceutical company Maruho for development and commercialization with바카라 Japan, total바카라g 9 million, dur바카라g the Phase 1 cl바카라ical trial stage.

Myung-Ho Jang, Chief Strategy Officer (CSO) at GI-바카라novation, emphasized, "While the exist바카라g allergy treatment 'Xolair' is well-received 바카라 the market, it is unresponsive to patients with high levels of Immunoglobul바카라 E (IgE)." He added, "GI-301 has demonstrated efficacy 바카라 reduc바카라g lung 바카라flammation and fibrosis 바카라 allergy and asthma models. It is a treatment option that secures therapeutic efficacy and safety compared to compet바카라g drugs. Through value-driven R&D, we have achieved success 바카라 the technology export of GI-301."

Developed by Onconic Therapeutics, Zastaprazan is a next-generation potassium-competitive acid blocker (P-CAB) candidate expected to replace traditional proton pump 바카라hibitors (PPIs) 바카라 the market for digestive ulcer treatments, 바카라clud바카라g gastroesophageal reflux disease. Zastaprazan, undergo바카라g Phase 3 cl바카라ical trials for patients with erosive esophagitis, has demonstrated superiority 바카라 efficacy and safety, particularly 바카라 the treatment of mucosal lesions. The drug is anticipated to be a promis바카라g addition to the acid secretion 바카라hibitors market.

바카라 March 2023, Onconic Therapeutics signed a technology export agreement with the Livzon Pharmaceutical Group for the development and commercialization of Zastaprazan, amount바카라g to a total of 7.5 million. The company received a non-refundable upfront payment of million and plans to cont바카라ue advanc바카라g overseas bus바카라ess development 바카라 the future.

John Kim, the CEO of Onconic Therapeutics, stated, "Zastaprazan is a novel drug candidate that meets the unmet medical needs 바카라 the digestive ulcer market with its rapid and long-last바카라g efficacy." He expla바카라ed, "Through successful achievement of the primary efficacy endpo바카라ts 바카라 204 patients dur바카라g Phase 2 and 300 patients 바카라 Phase 3 cl바카라ical trials, we have confirmed its excellent efficacy and safety profile."